PAWC
P.A.W. Capital Portfolio holdings
AUM
$51.9M
This Quarter Return
+55.79%
1 Year Return
+46.14%
3 Year Return
+74.13%
5 Year Return
+167.35%
10 Year Return
+839.74%
AUM
$93.8M
AUM Growth
+$93.8M
(+17%)
Cap. Flow
-$5.74M
Cap. Flow
% of AUM
-6.12%
Top 10 Holdings %
Top 10 Hldgs %
41.34%
Holding
68
New
7
Increased
10
Reduced
25
Closed
7
Top Buys
| 1 |
OptimizeRx
OPRX
|
$2.52M |
| 2 |
APTO
Aptose Biosciences, Inc.
APTO
|
$1.02M |
| 3 |
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
|
$963K |
| 4 |
Spyre Therapeutics
SYRE
|
$764K |
| 5 |
SIX
Six Flags Entertainment Corp.
SIX
|
$722K |
Top Sells
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$2.36M |
| 2 |
Regenxbio
RGNX
|
$1.23M |
| 3 |
MNDT
Mandiant, Inc. Common Stock
MNDT
|
$1.2M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$1.12M |
| 5 |
EverQuote
EVER
|
$962K |
Sector Composition
| 1 | Technology | 28.13% |
| 2 | Healthcare | 25.68% |
| 3 | Communication Services | 15.38% |
| 4 | Consumer Staples | 9.73% |
| 5 | Financials | 5.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Microsoft
MSFT
$3.72T
| $946K | 1.01% |
6,000
+1,000
| +20% | +$158K |
|
27
JPMorgan Chase
JPM
$820B
| $767K | 0.82% |
5,500
-500
| -8% | -$69.7K |
|
|
28
Spyre Therapeutics
SYRE
$1B
| $764K | 0.81% |
+100,000
| New | +$764K |
|
29
Carnival Corp
CCL
$41.9B
| $762K | 0.81% |
15,000
| – | – |
|
30
BP
BP
$90.6B
| $755K | 0.81% |
20,000
+4,000
| +25% | +$151K |
|
|
RDS.A
31
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $737K | 0.79% |
12,500
+500
| +4% | +$29.5K |
|
32
Johnson & Johnson
JNJ
$428B
| $729K | 0.78% |
5,000
| – | – |
|
33
Merck
MRK
$213B
| $728K | 0.78% |
8,000
| – | – |
|
|
SIX
34
DELISTED
Six Flags Entertainment Corp.
SIX
| $722K | 0.77% |
+16,000
| New | +$722K |
|
35
Dow Inc
DOW
$17.2B
| $711K | 0.76% |
13,000
-2,000
| -13% | -$109K |
|
36
AbbVie
ABBV
$373B
| $708K | 0.75% |
8,000
| – | – |
|
37
3M
MMM
$81.9B
| $706K | 0.75% |
4,000
+2,000
| +100% | +$353K |
|
38
GSK
GSK
$78.1B
| $705K | 0.75% |
15,000
-1,000
| -6% | -$47K |
|
39
Schlumberger
SLB
$53.5B
| $704K | 0.75% |
+17,500
| New | +$704K |
|
40
AT&T
T
$208B
| $703K | 0.75% |
18,000
-2,000
| -10% | -$78.1K |
|
41
Altria Group
MO
$113B
| $699K | 0.75% |
14,000
-1,000
| -7% | -$49.9K |
|
42
Abbott
ABT
$228B
| $695K | 0.74% |
8,000
| – | – |
|
43
Pfizer
PFE
$141B
| $686K | 0.73% |
17,500
| – | – |
|
44
PepsiCo
PEP
$207B
| $683K | 0.73% |
5,000
| – | – |
|
45
Philip Morris
PM
$261B
| $681K | 0.73% |
8,000
| – | – |
|
46
Verizon
VZ
$185B
| $675K | 0.72% |
11,000
-1,000
| -8% | -$61.4K |
|
47
Ares Capital
ARCC
$15.7B
| $671K | 0.72% |
36,000
-4,000
| -10% | -$74.6K |
|
48
Chevron
CVX
$326B
| $663K | 0.71% |
5,500
| – | – |
|
49
Wells Fargo
WFC
$261B
| $646K | 0.69% |
+12,000
| New | +$646K |
|
50
Kraft Heinz
KHC
$30.8B
| $643K | 0.69% |
20,000
| – | – |
|